Pharmaxis Ltd (AU:SNT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Syntara Limited has reached a significant milestone in its drug development efforts, completing recruitment for its Phase 2 trial of SNT-5505, targeting myelofibrosis, with interim results expected in December 2024. The company has also secured a A$2.5 million grant for a new trial in Germany to explore SNT-5505’s potential in treating high-risk MDS and CMML, further broadening its clinical scope. Additionally, Syntara raised $5 million to support its ongoing trials and appointed Tim Luscombe as the new CFO, strengthening its operational and financial position.
For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.